The Ireland-based company issued a statement confirming that it is engaged in “highly preliminary discussions” with Amgen, Janssen, and Sanofi. Any acquisition of Horizon Therapeutics would be among the biggest deals of 2022.
Tag Archive for: Sanofi
Britain’s medicines regulator said on Tuesday that any new or worsening reactions in patients’ eyes arising from use of Sanofi’s best-selling asthma and eczema drug Dupixent should be promptly reviewed by healthcare professionals.
Sanofi said on Thursday it won European Union approval for its COVID-19 vaccine booster, jointly made with British partner GSK, after a drawn-out development effort that saw the pair fall behind now-dominant vaccine suppliers.
Biogen Inc. on Thursday tapped former Sanofi boss Christopher Viehbacher as its new chief executive, betting on an industry veteran to help the U.S. drugmaker put behind it a series of setbacks for Alzheimer’s drug Aduhelm.
The FDA greenlit Libtayo plus chemotherapy to treat patients with advanced NSCLC irrespective of EGFR, ALK or ROS1 aberrations. It is the drug’s second approval in this space.
Sanofi inked a research collaboration and license agreement with Stockholm, Sweden-based Salipro Biotech, whose proprietary platform enables researchers to improve workflows for developing therapeutic antibodies or small molecules that target membrane proteins.
The European Commission has approved Sanofi and AstraZeneca’s Beyfortus for the prevention of a common and highly contagious type of respiratory infection in infants.
GSK beat third-quarter earnings forecasts on Wednesday and raised its 2022 estimate for the second time in four months, continuing its strong start as a standalone prescription medicine business since spinning off its consumer health unit.
French drugmaker Sanofi on Friday forecast faster earnings growth this year on strong demand for its bestselling drug Dupixent and for its flu vaccines, spurring a rise in its battered share price.
Most clinical-phase drug development projects fail due to a lack of efficacy in the intended disease indication. Employing virtual patients during the drug development process has the potential to help guide decisions around dosing and efficacy.